Edwards Lifesciences goes after another set of Medtronic patents

July 16, 2013 by Brad Perriello

Edwards Lifesciences wants a federal judge to invalidate a pair of patents covering nerve stimulation sensing technology owned by arch-rival Medtronic.

Edwards Lifesciences goes after another set of Medtronic patents

Edwards Lifesciences (NYSE:EW) wants a federal judge to rule that a pair of patents owned by arch-rival Medtronic (NYSE:MDT) are invalid because they aren't specific enough.

The patents – the so-called '741 patent for a "Method and system for nerve stimulation and cardiac sensing prior to and during a medical procedure" and the '829 patent for a "Method and system for nerve stimulation prior to and during a medical procedure – cover nerve stimulation technology.

Edwards and Medtronic have spent considerable time in courts around the world, each arguing that the other's transcatheter aortic valve implant infringes various patents. Medtronic acquired the beef along with CoreValve in a $700 million buyout in April 2009.

Sign up to get our free newsletters delivered straight to your inbox

Last week a court in Germany ruled that the CoreValve TAVI infringes an Edwards Lifesciences patent, forcing it to cede the German market to Edwards and its Sapien valve.

Comments